BABE Market Analysis and Reports | USA Conference Series

Market Analysis - BABE 2017

The pharmaceutical industry is a billion dollar global business empire. According to an OECD (Organization for Economic Cooperation and Development) report, an average OECD country spent 1.5% of its GDP on pharmaceuticals in the year 2015. ‘The rate of growth of pharmaceutical spending outdistances that of total health expenditures in ten of 25 countries, while being roughly equal in six countries. Both pharmaceutical and total health expenditures grew at a higher rate than the mean annual growth rate of GDP for the countries’ that include Ireland, Hungary, United States, Mexico, Australia, Korea, Canada, Slovak Republic, Spain, Luxembourg, OECD, Finland, Iceland, Netherlands, France, Sweden, Portugal, UK, Austria, Czech Republic, New Zealand, Germany, Switzerland, Norway, Denmark, Italy and Japan

Analyses of global market trends, with data from 2012, assessment from 2013, and projections of compound annual growth through rates (CAGRs) 2018.The North American market is estimated to reach nearly $79 billion in 2017 and is habitual to increase at a 7.8% compound annual growth rate to reach nearly $108 billion in 2020.

The global generics sector reached $272.8 billion in 2016. This sector is habitual to reach $310.9 billion in 2017 and $518.9 billion in 2018, with a compound annual growth rate (CAGR) of 11.9%.

The global market for generic drugs was worth $81 billion in 2008, $84 billion in 2009, and measurement to be $169.7 billion in 2014. Sales of U.S. generic drugs currently preponderate the market with $54 billion for the 2014. Japan’s generic drugs market is habitual to have the highest rate of growth among major markets at 12.2%, advanced from $5.4 billion in 2009 to $9.6 billion in 2014.By 2016, it is expected that the value of the total global generics sector will have risen to $359 billion. The North American market is expected to reach nearly $107 billion in 2016 with an increase of 7.9% compound annual growth rate annual growth rate and Emerging market to reach nearly $115 billion.

The worldwide pharmaceutical industry was make allowances intolerant of an expected $1 trillion in 2014. In 2013, worldwide pharmaceutical markets produced incomes of $983.1 billion. That year, North America (the US and Canada) come through 43% of offers, while Europe contributed 27.8%.

The United States is currently spending almost $250 billion a year for prescription drugs. If drugs were sold in a competitive market, without government-imposed patent monopolies, this might achieve savings up to $200 billion a year.

The world population is growing rapidly and is projected to raise from 7 billion in 2011 to 7.7 billion in 2020 and 9.6 billion in 2050, hence an increase in the demand for pharmaceuticals. The global pharmaceuticals market is worth US$300 billion a year, a figure expected to rise to US$400 billion within three years. Economically, the Middle East (ME) is well positioned to be the one of next growth engine of global pharmaceutical business: several countries in the region enjoy robust economic growth and the highest cash reserves per capita in the world. The pharmaceutical Industry is consequently flourishing as the expanding middle class demands better care, and government healthcare spending continues to grow by 2020 about 9.4% of the world population (719.4 million people) will be 65 or above, compared with 7.3% (477.4 million) in 2005 (UN, 2013). Clinical advances reinforce this trend. The improvements of the past few decades have already converted some previously terminal illnesses into chronic conditions, thus increasing long-term demand for therapies to manage these diseases. Older people consume more medicines than younger people: four in five of those aged over 75 take at least one prescription product, while 36% take four or more. Therefore, the population age structure makes it possible to forecast an increase in the demand for medicines in this age group. Many producers of original medicines will have their patents expire very shortly. This “patent cliff” and the mass production of generics will cause a significant reduction in prices as a result of which the income of the pharmaceutical market will decrease by $148 billion between 2012 and 2018.

An overview of the global market of drugs, including coverage of therapeutics such as anticancer agents, antidepressants, anti-arthritics, antibacterial drugs, cardiovascular drugs sector is assessment to grow to $38.8 billion in 2018, with a compound annual growth rate (CAGR) of 27.5% from 2013 to 2018.

The medication fabricating class, the major traded on an open market organizations incorporate Johnson and Johnson, Novartis AG (NVS), Pfizer Inc. (PFE), Merck, Sanofi, and GlaxoSmithKline.

Analyses of global market trends, with data from 2012, guesstimate for 2013, and projections of compound annual growth rates (CAGRs) through 2018.The North American market is guesstimate to reach nearly $73 billion in 2011 and is expected to increase at a 7.9% compound annual growth rate to reach nearly $107 billion in 2016. The United States is currently spending almost $250 billion a year for prescription drugs. If drugs were sold in a competitive market, without government-imposed patent monopolies, this might achieve savings up to $200 billion a year.

The clinical trials market has been estimated to reach USD 14.2 billion in 2016 and is predetermined to reach around USD 22 billion by the year 2021, growing at a CAGR (compounded annual growth rate) of 7.5%, during the valuated  period 2016 to 2021. Clinical trial is a part of clinical research that follows a moderate protocol. Clinical trials are extraordinarily achieved to get data on safety and efficacy of the new developed drug. Clinical trial data is indispensable for further approval of the drug and to boost it into the market.

An overview of the global market of drugs, in addition to coverage of therapeutics such as antibacterial, antidepressants, anticancer agents, anti-arthritics, cardiovascular drugs sector is habitual to reach $300.9 billion in 2013 and $518.5 billion in 2018, with a compound annual growth rate (CAGR) of 11.5%.

As per market researchers, the global biosimilar market is expected to be worth $24 billion in 2019-at compound annual growth rate (CAGR) of some 65% from 2014.Clinical trials at global level would incur a nearly cost of few hundred crores. The expected cost of developing biosimilar for global markets is $75-250 million, while developing traditional non-biologic generics costs about $2-3 million. With the introduction of Inflectra on April 06, 2016 the Biosimilars Market will grow at even higher rate.

The increasing disease burden is mobilizing the pharmaceutical and biotechnology industry to bring up new chemical entities into the market at a higher rate. Most companies are redistributing the clinical trials of their newly developed drugs to various contract research organizations as this could save them the inconvenience of regulatory issues and patient recruitment burden from the research and development phase.

The global biosimilar market is growing at an exponential rate. The CAGR from 2015 to 2020 is projected at over 22%. The biosimilar market is habitual to be around $6.2 billion by 2020 from only $2.3 billion in 2015. By the end of this decade the biosimilar would surely cover 27% of the total pharmaceutical market. Moreover, with the global rise in concern for more accessible-improved- cost effective healthcare, biosimilar drugs would be a more apt choice to the payers, end users, manufacturers over the costly reference biologics. Originator biologics are as costly as about $100,000 per year per patient. Biosimilar on the contrary can be offered at a 30-40% lower price than that of the reference product. However, with all the success stories and opportunities there also lies a sobering 50% failure rate in developing and obtaining license towards marketing of biosimilars.